This document discusses methods to reduce subjectivity in measuring nuclear pleomorphism in breast cancer images. It defines pleomorphism as variation in cell and nuclear size, shape, and color. Current grading methods rely on manual pathologist assessment, which can vary between pathologists. The document proposes detecting cell nuclei using color deconvolution and segmentation algorithms like U-Net to enable more objective pleomorphism scoring. Features would then be extracted from segmented nuclei and correlated with genetic biomarkers like TP53 mutations to validate the grading method. Future work includes further optimizing nuclei segmentation and feature extraction as well as validating the approach.